CN100482285C - 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途 - Google Patents

放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途 Download PDF

Info

Publication number
CN100482285C
CN100482285C CNB2004800260484A CN200480026048A CN100482285C CN 100482285 C CN100482285 C CN 100482285C CN B2004800260484 A CNB2004800260484 A CN B2004800260484A CN 200480026048 A CN200480026048 A CN 200480026048A CN 100482285 C CN100482285 C CN 100482285C
Authority
CN
China
Prior art keywords
specific binding
domain
antibody
binding member
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800260484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1849144A (zh
Inventor
劳拉·博尔西
芭芭拉·卡尔内莫拉
恩里卡·巴尔扎
帕特里齐亚·卡斯泰拉尼
卢恰诺·扎尔迪
马蒂亚斯·弗里贝
克里斯托夫-斯特凡·希尔格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Philogen SpA
Original Assignee
Schering AG
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG, Philogen SpA filed Critical Schering AG
Publication of CN1849144A publication Critical patent/CN1849144A/zh
Application granted granted Critical
Publication of CN100482285C publication Critical patent/CN100482285C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB2004800260484A 2003-09-10 2004-09-01 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途 Expired - Fee Related CN100482285C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/501,881 2003-09-10
EP03255633.4 2003-09-10
EP03255633A EP1514561A1 (en) 2003-09-10 2003-09-10 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Publications (2)

Publication Number Publication Date
CN1849144A CN1849144A (zh) 2006-10-18
CN100482285C true CN100482285C (zh) 2009-04-29

Family

ID=34130349

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800260484A Expired - Fee Related CN100482285C (zh) 2003-09-10 2004-09-01 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途

Country Status (27)

Country Link
US (2) US20050074401A1 (da)
EP (3) EP1514561A1 (da)
JP (1) JP2007505065A (da)
KR (1) KR101129161B1 (da)
CN (1) CN100482285C (da)
AT (1) ATE499949T1 (da)
AU (2) AU2004269897B2 (da)
BR (1) BRPI0414272A (da)
CA (1) CA2536256C (da)
CR (2) CR8331A (da)
DE (1) DE602004031635D1 (da)
DK (1) DK1663320T3 (da)
EA (1) EA010653B1 (da)
EC (1) ECSP066499A (da)
ES (1) ES2361743T3 (da)
IL (1) IL173560A0 (da)
ME (1) MEP13108A (da)
NO (1) NO20061619L (da)
NZ (1) NZ545640A (da)
PL (1) PL1663320T3 (da)
PT (1) PT1663320E (da)
RS (1) RS20060176A (da)
SG (1) SG162760A1 (da)
SI (1) SI1663320T1 (da)
UA (1) UA89759C2 (da)
WO (1) WO2005023318A1 (da)
ZA (1) ZA200602014B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
JP2005534283A (ja) * 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
EP2281006B1 (en) * 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
WO2014194784A1 (zh) * 2013-06-06 2014-12-11 合肥立方制药股份有限公司 人源抗纤连蛋白ed-b结构域的抗体及其用途
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
HRP20241274T1 (hr) 2020-05-22 2024-12-06 Philogen S.P.A. Terapija na bazi tnf-a imunokonjugata za liječenje tumora mozga
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
EP4440599B1 (en) 2022-01-04 2026-02-25 Philogen S.p.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
CN119775344B (zh) * 2024-12-31 2025-08-26 英科新创（苏州）生物科技有限公司 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
WO2003055917A2 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
PT1257297E (pt) 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
JP2005534283A (ja) * 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
WO2003055917A2 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Also Published As

Publication number Publication date
KR20060118430A (ko) 2006-11-23
CR8331A (es) 2006-10-04
HK1092375A1 (zh) 2007-02-09
CN1849144A (zh) 2006-10-18
AU2004269897B2 (en) 2009-11-05
PL1663320T3 (pl) 2011-07-29
IL173560A0 (en) 2006-07-05
NZ545640A (en) 2009-05-31
MEP13108A (en) 2011-05-10
EP1514561A1 (en) 2005-03-16
ATE499949T1 (de) 2011-03-15
CA2536256C (en) 2013-02-26
RS20060176A (sr) 2008-08-07
US20050074401A1 (en) 2005-04-07
AU2004269897A1 (en) 2005-03-17
AU2010200271A1 (en) 2010-02-18
DE602004031635D1 (de) 2011-04-14
NO20061619L (no) 2006-04-10
JP2007505065A (ja) 2007-03-08
ECSP066499A (es) 2006-10-10
DK1663320T3 (da) 2011-06-06
EP2246070A2 (en) 2010-11-03
PT1663320E (pt) 2011-06-07
EP1663320A1 (en) 2006-06-07
EA200600494A1 (ru) 2006-08-25
WO2005023318A1 (en) 2005-03-17
SI1663320T1 (sl) 2011-06-30
ES2361743T3 (es) 2011-06-21
US20090214423A1 (en) 2009-08-27
ZA200602014B (en) 2007-05-30
CA2536256A1 (en) 2005-03-17
EA010653B1 (ru) 2008-10-30
BRPI0414272A (pt) 2006-11-07
UA89759C2 (ru) 2010-03-10
KR101129161B1 (ko) 2012-03-28
CR20110168A (es) 2011-06-03
SG162760A1 (en) 2010-07-29
EP1663320B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US20090214423A1 (en) Selective targeting of tumor vasculature using radiolabelled antibody molecules
CN100535013C (zh) 应用抗体分子对肿瘤血管进行选择性定向
JP4663020B2 (ja) 腫瘍の新しい診断および治療方法
US9765155B2 (en) Covalent disulfide-linked diabodies and uses thereof
HK1092375B (en) Use of radiolabelled antibody l19 against fibronectin ed-b in the preparation of a medicament for targeting of tumor vasculature
MXPA06002757A (en) Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b
PT1461360E (pt) Conjugados compreendendo um anticorpo específico para o domínio ed-b de fibronectina e suas utilizações para a detecção e tratamento de tumores
HK1076474B (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092375

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: Italy, Siena

Co-patentee after: BAYER SCHERING PHARMA AG

Patentee after: PHILOGEN S.P.A.

Address before: Italy, Siena

Co-patentee before: Schering AG

Patentee before: PHILOGEN S.P.A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1092375

Country of ref document: HK

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Italy Siena

Patentee after: PHILOGEN S.P.A.

Address before: Italy Siena

Co-patentee before: Bayer Pharma AG

Patentee before: PHILOGEN S.P.A.

Address after: Italy Siena

Co-patentee after: BAYER PHARMA AG

Patentee after: PHILOGEN S.P.A.

Address before: Italy Siena

Co-patentee before: BAYER SCHERING PHARMA AG

Patentee before: PHILOGEN S.P.A.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090429

Termination date: 20170901

CF01 Termination of patent right due to non-payment of annual fee